share_log

HC Wainwright & Co. Maintains Neutral on Kyverna Therapeutics, Lowers Price Target to $4

Benzinga ·  Apr 3 11:28

HC Wainwright & Co. analyst Mitchell Kapoor maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Neutral and lowers the price target from $6 to $4.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 221

Recommended

Write a comment